The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Once-Weekly Semaglutide in Adolescents with Obesity
Open accessAbstract
BACKGROUND: A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS: In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention. The primary end point was the percentage change in BMI from baseline to week 68; the secondary confirmatory end point was weight loss of at least 5% at week 68. RESULTS: A total of 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001). At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo. The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%). Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis. Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group. CONCLUSIONS: Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approved by FDA/EMA from age 12.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“73% achieved ≥ 5% weight loss and with significant amelioration of CVD factors (e.g. waist circumference, ALT and HbA1c) and no adverse impact on pubertal development and bone health [113].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar efficacy was achieved with once-weekly subcutaneous injections of 2.4 mg semaglutide in the STEP Teens trial among adolescents aged 12–18 years [80]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“In the STEP TEENS trial, adolescents achieved a − 16.1% mean BMI reduction vs. + 0.6% in the placebo group.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
In the citing paper
“Similar efficacy was achieved with 2.4 mg once weekly injections in adolescents with comorbidities (STEP Teens) and with a high dose (50 mg once daily) of the oral formulation of semaglutide in adults (OASIS-1) [24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“However, weight loss was less amongst obese individuals with T2DM (eg 9.6% weight loss with the 2.4 mg once weekly injected semaglutide in STEP-2) for likely reasons described above [17, 24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“the main trials for which data have been published (STEP 1 through STEP 5, STEP 8, and STEP TEENS) did not include participants who reported having symptoms of major depressive disorder within 2 years before screening, which limits their ability to assess psychiatric adverse events in people with a recent history of depression [3,4,93,94,95,96,97].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [97]
In the citing paper
“STEP TEENS studied semaglutide 2.4 mg in adolescents living with obesity and reported that semaglutide versus placebo resulted in a 17.7-kg weight loss over 68 weeks (Table 3B).76”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Overweight in Children and Adolescents
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., Robinson, T. N., Scott, B. J., Jeor, S. S., & Williams, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000161369.71722.10 · Cited by 1,543
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationStyne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,375
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Kelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 794
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 4
A Growing Burden: Obesity’s Impact on Cardiometabolic Disease Risk in Children and Adolescents
Catalfamo, V. J., Farhud, S., Mulkey, J., & Lavie, C. J. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02341-5 · Cited by 4
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 4
Strathe, A., Bomberg, E. M., Jensch, G., Kildegaard, J., Harder-Lauridsen, N. M., Weghuber, D., & Overgaard, R. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70678 · Cited by 4
Self-citationManagement of Childhood Obesity
Gad, H., Dauleh, H., Mohammed, I., Malik, R. A., & Hussain, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083528 · Cited by 4
Venu, S., & Raj, M. (2026) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2025-003846 · Cited by 4
Current pharmacotherapy options in pediatric obesity
Malíková, J. K., Hainerová, I. A., & Lebl, J. (2023) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2023/017 · Cited by 4
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease
Zachariah, J. P. V. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01114-1 · Cited by 5
Pediatric Obesity Care via Telemedicine: Expanding the Path Forward—A Review
O’Hara, V. M., Louder, D., Johnston, S. V., Hastey, K., & Browne, N. T. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00537-w · Cited by 4
Vidmar, A. P., Kaiser, L., Martin, M. J., Abel, S. A., Kim, A. G., Weitzner, M., Muñoz, C. E., Fisher, L. K., Kim, M. S., & Samakar, K. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05047-y · Cited by 4
Drastal, M., de Ferranti, S. D., & Gooding, H. C. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001460 · Cited by 4
Ni, M., Chen, Y., Gu, W., Zhang, Y., Xu, M., Gu, Y., Chen, Y., Zhu, Y., Wang, X. D., Luo, Y., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70090 · Cited by 4
Semaglutida no tratamento de obesidade e sobrepeso
de Oliveira, I. P., Lino, F. G., Rabano, J. L. R., Silva, J. R., de Oliveira, L. Z., Pezzotto, P., Miranda, T. L. M., Brunhara, V. G., de Oliveira, É. À., & Rocha, C. M. (2023) · Research Society and Development · doi:10.33448/rsd-v12i3.40656 · Cited by 4
Þorsteinsdóttir, S., Bjarnason, R. G., Eliasdottir, H. G., & Ólafsdóttir, A. S. (2023) · Nutrients · doi:10.3390/nu15122788 · Cited by 4
Semaglutide as a chance for obesity treatment
Giordano, U., Kobiałka, J., & Pilch, J. (2023) · Medical Research Journal · doi:10.5603/mrj.a2023.0034 · Cited by 4
Pädiatrische Versorgungstrukturen bei Adipositas 2023 – Wo stehen wir?
Torbahn, G., Lischka, J., Joisten, C., & Weghuber, D. (2023) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-023-01804-9 · Cited by 4
Self-citationCerroni, C., Steiner, A., Seanez, L., Kwon, S., & Lewis, A. S. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137299 · Cited by 4
Are GLP-1R agonists the long-sought-after panacea for obesity?
Dowsett, G. K. C., & Yeo, G. S. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.06.008 · Cited by 5
Jewell, M. L. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad263 · Cited by 4
Rehman, R. (2025) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v14.i3.105731 · Cited by 3
Pattern of semaglutide prescription in a real-world Canadian patient cohort
Farahvash, A., Lee, M. C. M., Jain, R., & Jaakkimainen, L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.006 · Cited by 4
Semaglutide and the skin: A brief review of dermatologic implications
Salam, A., & Hyder, M. S. (2025) · Cosmoderma · doi:10.25259/csdm_97_2025 · Cited by 3
Liang, L., Chen, J., Zhu, J., Kang, Z., Sun, B., & Zhang, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c05665 · Cited by 3
Youth-onset type 2 diabetes: Advances, treatments, and challenges in prevention
Sparling, D. P., & Tryggestad, J. B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.020 · Cited by 3
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
Wang, Y., Oza, N., Chirapongsathorn, S., Lee, S. Y., Tan, E. X. X., Lee, G. H., Teng, M. L. P., Leo, J., Ng, C., Ng, C. H., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113004 · Cited by 3
Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report
Liekens, L., Kaïret, K., & Elst, E. F. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10909 · Cited by 3
Ethical considerations for semaglutide use in children
Ryan, N., Wilkinson, D., & Savulescu, J. (2026) · Archives of Disease in Childhood · doi:10.1136/archdischild-2025-329747 · Cited by 3
The ethics of wegovy for children: the argument from too many unknowns
Ryan, N., & Savulescu, J. (2026) · Bioethics News · doi:10.1007/s40592-025-00280-z · Cited by 3
Obesity Hypoventilation Syndrome in Children and Adolescents
Petrongari, D., Filippo, P. D., Cacciatore, F., Ludovico, A. D., Papa, G. F. S., Pillo, S. D., Chiarelli, F., & Attanasi, M. (2026) · Children · doi:10.3390/children13010140 · Cited by 3
Granados, I., Wolfgang, K. M., Arasteh, K., Viswanathan, K., Snyder, M., Bunnell, H. T., & Phan, T.-L. T. (2026) · Obesity · doi:10.1002/oby.70128 · Cited by 3
Obesity in children and adolescents
Berman, C., Kohn, B., & Wilson, D. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.004 · Cited by 5
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 4
Nehushtan, H., Elrajabi, R., Peyyety, V., Apte, S., Chivate, R., Anderson, A., Jankowski, M., Tas, E., March, C. A., Christian, C., et al. (2026) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2026.03.017 · Cited by 3
Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management
Wan, K., Lei, E. F., Liu, Y., Taddese, A. A., Ip, P. C. T., Torbahn, G., Weghuber, D., Huang, W. Y., & Tam, B. T. (2026) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2026.2248 · Cited by 3
Self-citationSoliman, A. T., Alyafei, F., Khalil, A., Kardousha, A., Ahmed, S., Alaaraj, N., & Hamed, N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113400 · Cited by 3
Current options in obesity pharmacotherapy for children and adolescents
Jung, H. W. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00093 · Cited by 3
Should young kids take the new anti-obesity drugs? What the research says
Nowogrodzki, J. (2024) · Nature · doi:10.1038/d41586-024-02983-5 · Cited by 3
Raatz, S. J., FREESE, R. L., Jang, S., Kunin‐Batson, A., Gross, A. C., & Bensignor, M. O. (2024) · Childhood Obesity · doi:10.1089/chi.2024.0351 · Cited by 3
Glucagon-like peptide-1 (GLP-1) receptor agonists: applications in childhood diabetes and obesity
Hu, K., & Barrett, T. G. (2025) · Paediatrics and Child Health · doi:10.1016/j.paed.2025.01.003 · Cited by 3
Self-citationTrends in Glucagon-Like Peptide 1 Receptor Agonists Utilization for Weight Management in Children
Mak, D., Liu, D., Prodhan, P., & Bansal, S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0027 · Cited by 3
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone
Ferrara, F., Bazzani, D., Crivelli, B., Danieli, E., Gazzola, P., Guarnieri, G., Handschin, G., Lauria, C., Marchetti, C., Sbraga, E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04319-0 · Cited by 4
New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity
Dira, L.-M., Marin, L.-M., Popa, S. G., Singer, C.-E., Coşoveanu, C. S., Donoiu, I., & Golli, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136143 · Cited by 3
Challenges in the treatment of young people with type 2 diabetes
Madsbad, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00030-x · Cited by 3
Potential therapies for obesity management: Exploring novel frontiers
Chand, S., Dikkatwar, M. S., Varghese, T. P., Singh, R., Sah, S. K., Sutar, A. S., Biswas, J., & Shandily, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102382 · Cited by 3
Conroy, C., Radulescu, A., Attia, S. L., Shelman, N. R., Lee, J. T., Galuppo, R., Hall, S., Kohli, R., & Softic, S. (2024) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_428_23 · Cited by 3
Anesthesia considerations for pediatric metabolic and bariatric surgery
Manupipatpong, K., Wayne, C. D., Tobias, J. D., Nafiu, O. O., Michalsky, M. P., & Syed, A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.07.004 · Cited by 3
Diagnosis and Management of Hypertension in Adolescents with Obesity
Chhabria, S. M., LeBron, J., Ronis, S. D., & Batt, C. E. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00740-x · Cited by 3
MODERN VIEWS ON METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS
Velychko, V. I., Хацько, В. Е., Lahoda, D. O., Bazhora, Y. I., & Pencho, G. O. (2024) · doi:10.32782/2226-2008-2024-2-10 · Cited by 3
Genetic deletion of ITIH5 leads to increased development of adipose tissue in mice
Sessler, T. M., Beier, J. P., Villwock, S., Jonigk, D. D., Dahl, E., & Ruhl, T. (2024) · Biological Research · doi:10.1186/s40659-024-00530-0 · Cited by 3
Michalsky, M. P., Fox, C. K., & Pratt, J. S. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.10.018 · Cited by 3
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians
Laroche, H. H., Fernández, C., Sweeney, B. R., Gillette, M. L. D., & Hampl, S. E. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0005 · Cited by 3
Transparency in Science Reporting: A Call to Researchers and Publishers
Sturmberg, J. P., & Kühlein, T. (2025) · Cureus · doi:10.7759/cureus.79493 · Cited by 3
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 3
Treating Childhood Obesity: Building and Evaluating Evidence-Based Models of Integrated Care
McSweeney, Z. C., Antonelli, R. C., & Ebbeling, C. B. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf109 · Cited by 3
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Fang, H., Niu, B., & Chen, Q. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230416153301 · Cited by 3
Updates in the Treatment of Pediatric Obesity
Wright, T. F., Rivero, C. M., & Barlow, S. E. (2023) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-023-00270-5 · Cited by 3
The Economic Value of Treating Pediatric Obesity: Costs Are Not Keeping Up With Efficacy
Ryder, J. R., Lim, F., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36337 · Cited by 3
Pediatric obesity is a complex disease. It is time we start reimbursing for care
Armstrong, S. (2024) · Pediatric Research · doi:10.1038/s41390-024-03201-8 · Cited by 2
Innovative Care for Children and Adolescents with Severe and/or Genetic Obesity
Schirmer, M., Zorn, S., von Schnurbein, J., & Wabitsch, M. (2025) · Hormone Research in Paediatrics · doi:10.1159/000544177 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity
Edmondson, E. K., Shah, R. D., & Gregory, E. F. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2077 · Cited by 2
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment
Bensignor, M. O., Hsia, D. S., Name, M. A. V., Jastreboff, A. M., & Ryder, J. R. (2025) · Diabetes Care · doi:10.2337/dci25-0031 · Cited by 2
Exploring Challenges With Widespread Use of GLP-1–Based Therapies for Adolescents and Young Adults
Luo, J., Vajravelu, M. E., & Dusetzina, S. B. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2469 · Cited by 2
Lin, B., Huang, Q., Weng, L., & Lin, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1684204 · Cited by 2
Ethics of Lifestyle Counsel Alone in a GLP-1 Era
Stephenson, K. M., Schwartz, N. R. M., & Diekema, D. S. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3327 · Cited by 2
Péč, M. J., Jurica, J., Péčová, M., Nagy, N., Focko, B., Miertová, Z., Ferencová, N., Ságová, I., Tonhajzerová, I., Bolek, T., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091364 · Cited by 2
Tejeji, I., Zeier, T., SMITH, J. A., CHANG, N. T., & Chao, L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0493 · Cited by 2
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Hertzer, L., Siegel, R., Kharofa, R. Y., Stackpole, K., & Mahabee‐Gittens, E. M. (2026) · Childhood Obesity · doi:10.1177/21532176251413898 · Cited by 2
Lv, J., Zhang, S., Qu, Y., Cao, Y., Zhang, J., Dai, X., & Shi, L. S. (2026) · Health and Metabolism · doi:10.53941/hm.2026.100005 · Cited by 2
Saba, L., Acosta, A. J., Kelly, A. S., & Kumar, S. (2026) · Nutrients · doi:10.3390/nu18020303 · Cited by 2
Self-citationSalama, M., Hassan, D., Vairo, F. P. E., Lteif, A. N., Hentz, R., Olson, O., Pittock, S. T., Nofal, A. A., Creo, A. L., & Kumar, S. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70091 · Cited by 2
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
Chopra, H., Mehta, A., Ponde, C., Nanda, N. C., Wander, G., Oomman, A., KERKAR, D. P., Routray, S., Ratnaparkhi, G., Advani, P., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1375 · Cited by 2
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 2
Advancing child health: forecasting the next great research achievements
Cheng, T. L., Daniels, S. R., Snowden, J. A., & Glauser, T. A. (2026) · Pediatric Research · doi:10.1038/s41390-026-05126-w · Cited by 2
Cimador, V., Robertson, S., Desmond, C., Dodgson, J., van, B. E., Davis, N. L., & Moon, R. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70926 · Cited by 2
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 2
Cote, M. F., Oza, V. S., & Orlow, S. J. (2026) · Pediatric Dermatology · doi:10.1111/pde.70340 · Cited by 2
Hornick, M. A., Chao, G. F., Ying, L., Nadzam, G. S., Duffy, A. J., Ghiassi, S., Graetz, E., Gibbs, K. E., & Morton, J. M. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07374-3 · Cited by 2
Versorgungskonzepte für Kinder und Jugendliche mit extremer und/oder genetischer Adipositas
Zorn, S., Schirmer, M., von Schnurbein, J., Brandt, S., Göpel, E., Stein, R., Wiegand, S., Körner, A., Kühnen, P., & Wabitsch, M. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2292-1830 · Cited by 2
Approach to the Treatment of Children and Adolescents with Obesity
Hegedus, E., Vidmar, A. P., Mayer, M., Kohli, R., & Kohli, R. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.004 · Cited by 2
Update on diagnosis and management of childhood obesities
Martos‐Moreno, G. Á., & Argente, J. (2024) · ANALES RANM · doi:10.32440/ar.2024.141.02.rev07 · Cited by 2
Chien, T.-E., Chen, P., Chang, K., Hsu, C., Huang, H.-W., Tsai, S., Chen, Y., Chang, C.-H., Yang, H.-R., Tung, Y., et al. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.001 · Cited by 2
Can weight loss drugs like Ozempic treat obesity in children?
Lang, K. (2025) · BMJ · doi:10.1136/bmj.q2656 · Cited by 2
Management of Adolescent Obesity
Srivastava, G., Fatima, A., Madhar, A., & Paddu, N. U. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.002 · Cited by 2
Shaping the future of youth-onset type 2 diabetes: a call to action
SHAH, A. S., Kelsey, M. M., Wolf, R. M., & Nadeau, K. J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.003 · Cited by 2
The treatment of extreme obesity in adolescents and young adults with GLP-1 receptor agonists.
Brandt-Heunemann, S., Schirmer, M., Blüher, S., & Wabitsch, M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0250 · Cited by 2
Baden, C. S., Andersen, J. T., Christensen, M., & Gade, C. (2023) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000067 · Cited by 2
Malíková, J. K., & Lebl, J. (2023) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2023/024 · Cited by 2
The Role of Racism in Childhood Obesity
Lawton, R. I., & Stanford, F. C. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00538-9 · Cited by 3
Verhulst, S. L., de Perck, E. V., Slaats, M., Eyck, A. V., Hoorenbeeck, K. V., & Boudewyns, A. N. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10011323 · Cited by 2
PERIGOS E EFEITOS COLATERAIS DO USO DA SEMAGLUTIDA INJETÁVEL NO TRATAMENTO DA OBESIDADE
Oliveira, A. Z. D. P., de Oliveira, K. S., Coelho, O. S., Silva, D. R. G., & Gotardelo, D. R. (2024) · Revista Contemporânea · doi:10.56083/rcv4n5-231 · Cited by 2
PERIGOS E CONSEQUÊNCIAS DO USO INDISCRIMINADO DE OZEMPIC NO EMAGRECIMENTO
Bezerra, T. P. W., de Souza, P. C., Gomes, P. A. T. D. M., Ramalho, E. A. V. D. F., da Rosa, M. M., Pitta, M. G. D. R., Pitta, M. G. D. R., & Rêgo, M. J. B. D. M. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n6-004 · Cited by 2
Bieganek, P., Sadłowski, B., Łukaszewicz, S., Pawłowski, P., Rybak, J., Kordialik, J., Koćwin, J., Sarnacka, S., Tokarski, M. P., & Banasiak, A. (2024) · Health Problems of Civilization · doi:10.5114/hpc.2024.140505 · Cited by 2
Frelut, M. (2024) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(24)49678-5 · Cited by 2
Public health risks of approving drugs for the treatment of childhood obesity in Brazil
Vítolo, M. R., Baratto, P. S., & Deram, S. (2024) · Cadernos de Saúde Pública · doi:10.1590/0102-311xpt031624 · Cited by 2
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Chinn, J. O., Baidal, J. W., Pratt, J. S. A., Shepard, W. E., & Fell, G. L. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114610 · Cited by 2
Metadata
- Authors
- Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria (D.W.); the Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom (T.B.); the Division of Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Søborg, Denmark (D.H., O.K.J., R.S.); the Department of Pediatrics and the Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); the Division of Pediatric Endocrinology and Diabetes, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY (L.D.M.); and the Center for Pediatric Research in Obesity and Metabolism, Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine, and UPMC Children’s Hospital of Pittsburgh, Pittsburgh (S.A.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-15
- Volume
- 387
- Issue
- 24
- Pages
- 2245-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9997064
- OpenAlex
- W4308053954
- Cited by
- 730
- References
- 26
- Citations by year
- 2026: 217 · 2025: 199 · 2024: 189 · 2023: 120 · 2022: 5
- FWCI
- 76.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, adolescents, adolescent obesity, overweight, GLP-1 receptor agonists, weight loss, body mass index, cardiometabolic risk factors, lifestyle intervention, gastrointestinal adverse effects, gallstones, drug safety, weight-related comorbidities, HbA1c, alanine aminotransferase, waist circumference, serum lipids, serious adverse events
- MeSH terms
- Healthy Lifestyle, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Cutaneous, Adolescent, Child, Double-Blind Method, Humans, Weight Loss, Body Mass Index, Anti-Obesity Agents, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
